It’s here! Check out August's What’s Hot In Clots - a monthly digest of hot topics & trials in the world of #thrombosis with Dr. Behnood Bikdeli. Access this month’s full digest at: thrombosis.org/2024/08/whic-0… #bloodclots #healthcare #medicine

#AAA Attributed Mortality Trends in the US. New paper in JACC Journals w/ Vascular Medicine colleagues Behnood Bikdeli Gregory Piazza BWH Vascular Surgery CSPH Brigham and Women’s Department of Surgery jacc.org/doi/epdf/10.10…

Enjoyed collaborating with Gregory Piazza and Behnood Bikdeli on AAA attributed mortality, now published in JACC Journals Addressing modifiable CV risk factors will be an important strategy to reduce AAA mortality Gregory Piazza Behnood Bikdeli jacc.org/doi/abs/10.101…

🚨 New Special Issue Alert! 🚨 Check out the latest in Interventional Cardiology Clinics: "Antiplatelet & Anticoagulation Therapy in Cardiovascular & Pulmonary Embolism Transcatheter Interventions." 🫀💉#CardioTwitter #CVRjax 🔗 authors.elsevier.com/a/1jZyw7sv8qB4… sciencedirect.com/journal/interv…

Great review on perioperative managent of DOAC treated patients by Dr Douketis and Alex Spyropoulos from JAMA

Much debate & interesting ongoing studies RE the choice of advanced therapies in pts w #PulmonaryEmbolism. How do we use anticoagulation in these pts? 🤔 Our review of A/C regimens CardiologyClinics , great work by Álvaro Dubois Silva! sciencedirect.com/science/articl… #CardioTwitter #HemeTwitter

Home treatment for #PE: We have more evidence than ever before. For carefully selected pts, There is no place like 🏡 NEJM Group NEJM Journal Watch: jwatch.org/na57766/2024/0…

VTE recurrence after discontinuing anticoagulation in patients with VTE after receiving the vaccine against COVID-19 The #RIETEregistry experience appearing soon in EJCI

JACC Journals-ESC By the Numbers Of the 67 ESC simultaneous pubs in 9 JACC Journals: 50 in JACC, w/ - 6 Hotlines - 12 Late Breaking Science - 1 Featured Clin Res 4 in JACC Adv 3 in JACC Imag & JACC HF 2 in JACC Int & JACC CardioOnc 1 in JACC BTS, JACC EP & JACC Case Rep

I’m surprised that riva 2.5 BID + ASA is only a 2a recommendation. Data from VOYAGER PAD and COMPASS trials plus all secondary analyses are quite compelling

Seeking the Optimal Antithrombotic Therapy After Left Atrial Appendage Occlusion In a small trial, risk for bleeding or thrombotic events was lower with low-intensity direct oral anticoagulants than with dual antiplatelet therapy. jwat.ch/3X6wbk0 Behnood Bikdeli #cardiology

🚨ASSURE-DES results now in JACC Journals: Continue aspirin or stop it after noncardiac surgery. #Cardiotwitter Harlan Krumholz

Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery | Journal of the American College of Cardiology jacc.org/doi/10.1016/j.…

Need to 🤔 if ♀️♂️ differences in presentation, Tx, outcomes of #PE to do equitable care. First large study from China in Thrombosis Research #CURES: thrombosisresearch.com/article/S0049-… Editorial by McMaster University #DrBates & I: thrombosisresearch.com/article/S0049-… Connors Center for Women's Health & Gender Biology #thrombosis

How should we consider antithrombotic therapy in pts w #AF and stable #CAD? My summary of #EPIC_CAD trial NEJM NEJM Journal Watch #thrombosis North American Thrombosis Forum

#cardiology #cardiotwitter #cardioX #statistics JACC Journals Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai Mount Sinai Health System

JACC's commitment to authors comes from the top.

At JACC we move rapidly and wisely. Within 2d, 50% of submissions get a decision; within 7d, another 25%. We only send the most promising for review. We get many eyes on each submission. We are transforming medical publishing. #ESCCongress JACC Journals The Lancet Justine VarieurTurco

The antidote to overthinking isn't thinking less. It's rethinking more. Overthinking is ruminating on old ideas without a new lens. It narrows your focus and wears you out. Rethinking is revisiting the same issue from a different perspective. It broadens and sharpens your view.

In this #RPTH Original Article, authors report long-term outcomes from the OVID trial. Outpatients older than 50 w/ acute #COVID19 treated w/ Enoxaparin did not have improved functional or clinical outcomes at 2 yrs compared to standard of care Behnood Bikdeli rpthjournal.org/article/S2475-…